Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, specializing in the development of innovative treatments for central nervous system (CNS) diseases. Founded in 2004, the company is primarily focused on addressing significant unmet medical needs in conditions such as major depressive disorder and neuropathic pain. Its lead product candidate, d-Methadone, is an oral NMDA receptor antagonist currently in Phase II clinical trials, aimed at treating depression and other CNS-related disorders. Additionally, Relmada is developing other therapeutic options, including LevoCap ER, an abuse-resistant sustained-release formulation of levorphanol, BuTab, an oral formulation of buprenorphine, and MepiGel, a topical formulation of mepivacaine designated as an orphan drug. The company's commitment is to improve the lives of patients by advancing these promising therapies through clinical development.